Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Videos|March 30, 2022
Treat the Medical and Mental Health Challenges of Alopecia
Author(s)Mary Scoviak, Managing Editor
Christopher Bunick, MD, PhD, offered pointers on how to address the physical and mental aspects of this complex disease in this exclusive interview in conjunction with the American Academy of Dermatology 2022 Annual Meeting.
Advertisement
Last night’s so-called “slap heard round the world” when actor Will Smith slapped Oscar host Chris Rock after Rock’s controversial comment on Jada Pinkett Smith’s hair loss brought the issues surrounding alopecia to the international forefront. Christopher Bunick, MD, PhD, offered pointers on how to address the physical and mental aspects of this complex disease in this exclusive interview in conjunction with the American Academy of Dermatology 2022 Annual Meeting.
Advertisement
Related to this article
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
The 4-day CME meeting in Las Vegas offers up to 24.25 credits and sessions on inflammatory skin disease, skin cancer, pediatric dermatology, aesthetics, and more.
A biopsy-based analysis from the JADE MOA trial presented at EADV 2026 found reductions in pathogenic skin-resident memory T cells alongside restoration of epidermal barrier integrity.
Explore dermatology conferences and meetings taking place this October, including clinical updates, skin of color education, and pediatric dermatology research.
From next-generation oral therapies and long-term disease control to precision medicine, EADV 2026 highlighted a dermatology landscape increasingly focused on deeper, durable, and individualized outcomes.
The final day of EADV 2026 explored precision medicine, molecular profiling, atopic dermatitis research, real-world evidence, and emerging approaches to individualized dermatologic care.
New EADV 2026 data highlighted real-world outcomes in adults with chronic hand eczema and improvements in itch, pain, and quality of life among adolescents treated with delgocitinib cream.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Remibrutinib for Symptomatic Dermographism
2
Abrocitinib Reduces Pathogenic Skin-Resident Memory T Cells in Atopic Dermatitis
3
Previewing the 2026 Fall Clinical Dermatology Conference
4
Personalized Prescription Skin Care: Curology’s Whitney Tolpinrud, MD, on the Evolution of Virtual Dermatology
5